BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of October 12, 2026, BCTX stock price declined to $3.87 with 23,743 million shares trading.

BCTX has a beta of 2.06, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.07 to the broad based SPY ETF.

BCTX has a market cap of $33.67 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCTX traded as high as $895.50 and as low as $2.60.

BCTX has underperformed the market in the last year with a price return of -69.4% while the SPY ETF gained +17.1%. However, in the short term, BCTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.3% vs +3.8% return in SPY. But in the last 2 weeks, BCTX shares have been beat by the market, returning -10.3% compared to an SPY return of +0.9%.

BCTX support price is $3.72 and resistance is $4.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.